Research Analysts’ Recent Ratings Changes for Structure Therapeutics (GPCR)

Structure Therapeutics (NASDAQ: GPCR) recently received a number of ratings updates from brokerages and research firms:

• 3/28/2026 – Structure Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 3/26/2026 – Structure Therapeutics is now covered by Wolfe Research. They set a “peer perform” rating on the stock.
• 3/17/2026 – Structure Therapeutics was given a new $145.00 price target by BMO Capital Markets. They now have an “outperform” rating on the stock.
• 3/16/2026 – Structure Therapeutics had its “outperform” rating reaffirmed by William Blair.
• 3/16/2026 – Structure Therapeutics had its “outperform” rating reaffirmed by Leerink Partners.
• 3/16/2026 – Structure Therapeutics had its price target lowered by HC Wainwright from $114.00 to $100.00. They now have a “buy” rating on the stock.
• 3/2/2026 – Structure Therapeutics had its price target raised by HC Wainwright from $90.00 to $114.00. They now have a “buy” rating on the stock.
• 2/28/2026 – Structure Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 2/27/2026 – Structure Therapeutics had its price target lowered by Citizens Jmp from $120.00 to $113.00. They now have a “market outperform” rating on the stock.
• 1/31/2026 – Structure Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.